Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.

Abstract

Aclarubicin (ACM) was administered as induction treatment to 40 patients with acute myeloid leukemia (AML) who were either refractory to initial induction chemotherapy or in relapse. Thirty-eight patients with AML, 2-80 years of age (mean +/- SE, 35.0 +/- 3.2), were evaluated during this study. Seventeen of these patients were given ACM after an unsuccessful attempt had been made to attain a complete remission (CR) with various regimens that included doxorubicin or daunorubicin; this group was considered resistant to these drugs. ACM was administered by rapid iv injection. Thirteen patients received a single course of ACM at a daily dose of 10-30 mg/m2 until a maximum total dose of 300 mg/m2 was reached or until unacceptable toxicity appeared. Of these patients, two (15%) attained a CR. The other 25 patients were given 10-day courses of ACM at a daily dose of 15 mg/m2 with 10-day intervals between courses; courses were repeated until the blast cells were cleared from peripheral blood and bone marrow or until progressive disease became evident. With this regimen, 11 patients (44%) attained a CR. The overall CR rate for the 38 patients was 34%. Total doses necessary to achieve a CR ranged from 150 to 600 mg/m2. A CR was attained by six patients who were previously resistant to a regimen containing moderate doses of doxorubicin. The incidence and severity of the toxic effects were related to the dose of ACM administered per course of therapy. The incidence of mucositis, diarrhea, vomiting, and infection in patients who received doses greater than 150 mg/m2/course was significantly higher than that observed in patients who received a dose of 150 mg/m2/course. In the latter patients, toxicity was within acceptable limits. Alopecia was not observed. Three patients had transient T-wave inversion, and reversible atrial flutter developed in one patient. Our results indicate that ACM is a major new drug for the treatment of AML.

• Authors: D Machover, J Gastiaburu, M Delgado, E Goldschmidt, R Hulhoven, J L Misset, F de Vassal, H Tapiero, P Ribaud, L Schwarzenberg
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 68 Issue 6 Pg. 881-6 (Jun 1984) ISSN: 0361-5960 [Print] United States
• PMID: 6587933 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Naphthacenes
• Aclarubicin

Topics

• Aclarubicin
• Adolescent
• Adult
• Aged
• Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Leukemia, Myeloid, Acute (drug therapy, pathology)
• Male
• Middle Aged
• Naphthacenes (administration & dosage, adverse effects, therapeutic use)